PCR

The computed 12-month bankruptcy probability of PCR is 1.5% (moderate). The annual accounts of PCR for financial year 2025 show a net loss of 51% of the equity at the start of that year. The 2025 annual accounts show equity of €14,802 and a net result of -€15,397. Its solvency ranks better than 28% of 1,807 sector peers (NACE 77, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals.